Artes Medical, Inc. Files Registration Statement with the SEC for Proposed Initial Public Offering

Artes Medical, Inc. announced today that it has filed a
registration statement with the Securities and Exchange Commission for
a proposed initial public offering of its common stock. The number of
shares to be offered and the price range of the proposed offering have
not yet been determined. All of the shares of common stock will be
offered by the Company.
Cowen and Company, LLC and Lazard Capital Markets LLC will act as
joint book-running managers of the proposed offering. Stifel, Nicolaus
& Company, Incorporated will act as co-manager of the proposed
offering. The proposed offering will be made only by means of a
prospectus. When available, copies of the preliminary prospectus
relating to this proposed offering may be obtained from the Securities
and Exchange Commission website at www.sec.gov or by contacting either
Cowen and Company, LLC or Lazard Capital Markets LLC c/o ADP Financial
Services, 1155 Long Island Ave., Edgewood, NY 11717 or by fax (631)
254-7268.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission but has not yet
become effective. These securities may not be sold nor may offers to
buy these securities be accepted prior to the time that the
registration statement becomes effective. This news release shall not
constitute an offer to sell or the solicitation of an offer to buy nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction. The prospectus related to the
proposed offering will be included in the registration statement.

About Artes Medical

Artes Medical, Inc. is a fully integrated medical technology
company focused on developing, manufacturing and commercializing a new
category of permanent aesthetic micro-injectable products for the
dermatology and plastic surgery markets. The Company's initial product
candidate, ArteFill, is currently under review by the U.S. Food and
Drug Administration for the correction of facial wrinkles known as
smile lines, or nasolabial folds. Artes Medical, Inc. was founded in
1999, and is based in San Diego, California.

Cautionary Statement

This news release contains forward-looking statements that are
based on the Company's current beliefs and assumptions and on
information currently available to its management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. As a result of these risks, uncertainties
and other factors, readers are cautioned not to place undue reliance
on any forward-looking statements included in this press release.
These forward-looking statements represent beliefs and assumptions
only as of the date of this news release, and the Company assumes no
obligation to update these forward-looking statements publicly, even
if new information becomes available in the future.